We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for enhanced S-cone syndrome (ESCS). The disease has autosomal recessive inheritance, a prevalence of less than one per million, and is caused by mutations in the NR2E3 gene. Clinical diagnosis is based on clinical findings, ophthalmological examination, electroretinography, color vision testing and optical coherence tomography. The genetic test is useful for confirming diagnosis, and for differential diagnosis, couple risk assessment and access to clinical trials.
General information about the disease
Enhanced S-cone syndrome (ESCS) is a rare progressive vitreoretinal dystrophy with early childhood onset, characterized by reduced bilateral visual acuity (from 20/40 to 20/200), hyperopia, subcapsular cataract, hemeralopia, night blindness and increased sensitivity to blue light. . Hyperopia and subcapsular cataract are common associated findings. Other signs related to a severe form, also called Goldman-Favre syndrome, include progressive pigment changes, macular edema or cysts, and foveal retinoschisis.
The estimated prevalence of ESCS is less than one per million. Diagnosis of ESCS is based on clinical findings, ophthalmological examination, characteristic electroretinographic pattern (1), and optical coherence tomography evidence of retinal thickening (2) . The diagnosis is confirmed by molecular genetic analysis of the responsible gene.
Differential diagnosis should consider X-linked retinoschisis, Wagner disease and retinitis pigmentosa.
ESCS is inherited in an autosomal recessive manner and the only known causative gene is NR2E3 (previously named PNR) (OMIM gene: 604485; OMIM disease: 268100).
Pathogenic variants may include sequence variations (small intragenic deletions/insertions, splice-site, missense and nonsense variants). Typically, exon or whole-gene duplications/deletions are not detected.
Aims of test
• To determine the gene defect responsible for the pathology • To confirm clinical diagnosis of the disease • To determine carrier status for the disease.
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Test characteristics Experts centers/Published guidelines
The test is listed in the Orphanet database and is offered by 6 accredited medical genetic laboratories in the EU, and in the GTR database, offered by 7 accredited medical genetic laboratories in the US.
The guidelines for clinical use of the test are described in "Genetics home reference" (ghr.nlm.nih.gov) and "American Academy of Ophthalmology" (aao.org).
Test strategy
Sanger sequencing is used for the detection of nucleotide variations in coding exons and flanking introns in the NR2E3 gene. Sanger sequencing is also used for family segregation studies. To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml blood in a sterile tube with 0.5 ml K3EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated. Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.
Genetic test results

Positive
Identification of pathogenic variants in NR2E3 confirms the clinical diagnosis and is an indication for family studies. A pathogenic variant is known to be causative for a given genetic disorder based on previous reports or predicted to be causative based on the loss of protein function or expected significant damage to protein or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.
Inconclusive
Detection of a variant of unknown or uncertain significance: a new variation and/or without any evident pathogenic significance or with insufficient or significant conflicting evidence to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives in order to assess variant segregation and clarify its contribution. In some cases it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.
Negative
The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:
• alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments; • sequence variations in gene regions not investigated by this test, such as regulatory regions (5' and 3' UTR) and deep intronic regions;
• variations in other genes not investigated by the present test.
Unexpected
Unexpected results may come out from the test, for example information regarding consanguinity; absence of family correlation or the possibility of developing genetically based diseases.
Risk for progeny
Autosomal recessive transmission needs that both healthy carrier parents transmit their disease variant to his/her children. In this case, the probability of having an affected boy or girl is therefore 25%.
Limits of the test
The test is limited by current scientific knowledge regarding the genes and disease. 
Prescription appropriateness
The genetic test is appropriate when: a) the patient meets the diagnostic criteria for the disease; b) the genetic test has diagnostic sensitivity greater than or equal to other published tests.
Clinical utility
Clinical management Utility
Confirmation of clinical diagnosis yes
Differential diagnosis yes
Access to clinical trial (7) yes
Couple risk assessment yes
